Serum fasting GLP-1 and GLP-2 associate with intestinal adaptation in pediatric onset intestinal failure

Annika Mutanen*, Mikko P. Pakarinen

Section of Pediatric Surgery, Pediatric Liver and Gut Research Group, Children’s Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland

**Article info**

Article history:
Received 9 June 2016
Accepted 4 September 2016

Keywords:
Parenteral nutrition
Short bowel syndrome
Children

**Summary**

**Aim:** Glukagon-like-peptide-1 (GLP-1) and -2 (GLP-2), produced by intestinal L-cells, are key hormones regulating intestinal transit, secretion, absorption, and mucosal growth. We evaluated naïve fasting serum GLP-1 and GLP-2 levels in pediatric intestinal failure (IF).

**Methods:** Fifty-five IF patients with median age 4.2 (IQR 1.3–12) years and 47 matched healthy controls underwent measurement of fasting serum GLP-1 and GLP-2.

**Results:** Serum GLP-2 [19.9 (13.8–27.9) vs 11.6 (7.0–18.6) ng/mL, P < 0.001], but not GLP-1 [6.1 (4.0–15.7) vs 6.4 (3.9–10.7) ng/mL, P = 0.976], levels were increased in IF patients. Serum GLP-2 concentrations were higher in patients with small bowel-colic continuity [21.1 (15.0–30.7) ng/mL] compared to patients with an endostomy [10.4 (6.6–17.9) ng/mL, P = 0.028], whereas no association with preservation of ileum or ileocecal valve was observed. During PN delivery, GLP-2 inversely associated with remaining small bowel length (r = −0.500, P = 0.041) and frequency of PN infusions (r = −0.549, P = 0.042). Serum GLP-1 levels were lower in patients receiving PN currently [4.1 (2.8–5.1)] compared to patients, who had weaned off PN [6.5 (5.1–21.1), P = 0.005], and correlated positively with duration of PN (r = 0.763, P = 0.002) and negatively with percentage parenteral energy requirement (r = −0.716, P = 0.006).

**Conclusions:** In pediatric IF, serum GLP-2 levels increase in patients with small bowel-colic continuity proportionally to the length of resected small intestine. Increase in serum GLP-1 and GLP-2 levels paralleled reducing requirement for parenteral support. These findings support regulation of intestinal adaption by GLP-2 and GLP-1 in children with IF.

© 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

1. Introduction

Intestinal failure (IF) results from a major bowel resection or congenital defect, leading to decreased intestinal absorptive area and malabsorption, rapid intestinal transit, and need for long-term parenteral nutrition (PN) to sustain adequate nutrition, growth and survival [1]. Following a massive small intestinal resection, intestinal adaptation, which involves a series of changes in intestinal morphology, function, and regulation, efforts to compensate for the loss of functional intestinal surface area, allowing gradual weaning of PN [2,3]. Intestinal adaptation is mediated by several endocrine hormones, including glucagon-like peptides (GLP) 1 and 2 synthesized by enteroendocrine L-cells of the distal small intestine and colon [4–6], GLP-1 inhibits gastric emptying and small intestinal and colon motility [7,8]. GLP-2 is shown to slow proximal intestinal motility, increase mesenteric blood flow, reduce gastric secretion, and to act as a trophic agent for the small intestinal mucosa improving nutrient absorption [9–11]. In patients with IF, lack of feed-stimulated GLP-2 response may lead to poor intestinal adaptation [4,5,12]. Discovery of enterotrophic effects of GLP-2 has led to novel emerging treatment options in patients with IF [13,14]. A GLP-2 analog teduglutide has been shown to improve nutrient and fluid absorption, endorse mucosal hyperplasia, and decrease PN requirement in IF patients [13,15,16].

In this study, we hypothesized that serum GLP levels are reflected by the extent and location of intestinal resection, intestinal continuity and PN requirement in pediatric onset IF. To test these hypotheses, we cross-sectionally measured fasting serum GLP-1 and GLP-2 levels in patients with pediatric onset IF and in controls matched for age and gender to investigate their relationships with intestinal adaptation during PN delivery and after weaning off PN.
2. Methods

2.1. Ethics

This study was approved by the Helsinki University Central Hospital ethics committee and the Institutional Review Board. A written informed consent was received from all patients and controls or their caregivers before any procedures.

2.2. Patients

Medical records of all patients with pediatric onset IF treated by our rehabilitation program in Children’s Hospital, Helsinki University Hospital from 1984 to 2014 were reviewed. In total, 72 eligible patients were identified of which 55 (76%) patients participated in this cross-sectional study, including clinical examination and laboratory tests. An informed written consent was received from patients and/or their parents.

For this study, IF was defined as over 50% resection of the small bowel or a duration of PN over 30 days [17,18], and patients with a primary intestinal dysmotility disorder such as Hirschsprung disease with less than 50% of age-adjusted small bowel length remaining were categorized to short bowel syndrome group. Our management protocol for IF has been reviewed recently elsewhere [19,20].

2.3. Controls

Forty-seven age and gender-matched healthy children and young adults without any renal, endocrinological, hepatobiliary or gastrointestinal disease, were used as controls. Their age [6.4 years (4.2–12), \textit{P} = 0.091] and sex (boys:girls, 35:12, \textit{P} = 0.144) distributions were comparable to patients.

2.4. Baseline data

Baseline patient data, including amount and composition of PN during 3 months preceding serum GLP-1 and GLP-2 measurement, surgical procedures and anatomy of the remaining bowel were collected from the patient records. Percentage of age-adjusted small bowel and colon length was calculated based on age-specific normal values [21]. The weight and height were expressed as z-scores. Body-mass index (BMI, in kg/m²; weight divided by the square of height) was calculated for adults and Finnish reference value-based BMI-for-age was calculated for children over two years of age [22].

2.5. Laboratory tests

Blood samples were drawn after overnight fast, prepared with centrifugation and stored to −20 °C until analyzed. Quantification of serum GLP-1 and GLP-2 were performed with the Human GLP-2 (YK141) and GLP-1 (YK160) EIA kits (Yanaihara Institute Inc., Shizuoka, Japan) according to the manufacturer’s instructions. The intra-assay and inter-assay CV (%) were 4.7 and 9.6 for GLP-1 and 3.0 and 14.3 for GLP-2, respectively. Serum citrulline, a marker of enterocyte mass, was measured by using an automatic amino acid analyser (Biochromon 30 Physiological and Midas Autosampler, Biochromon Limited, Cambridge, England) as described previously [23].

2.6. Statistical analysis

Descriptive statistics are expressed as median (IQR) unless otherwise stated. For multiple comparisons Kruskall Wallis test was used, followed by post hoc Mann Whitney U test when Kruskall Wallis test reached statistical significance. For pairwise comparisons Mann Whitney U test and Fisher’s exact test was used. Associations were tested with Spearman rank correlation test. Statistical significance was set at 0.05.

3. Results

3.1. Patient characteristics

Patient characteristics are shown in Table 1. Causes of IF included necrotizing enterocolitis (\textit{n} = 23), midgut volvulus (\textit{n} = 10), small bowel atresia (\textit{n} = 9), extensive Hirschsprung’s disease (\textit{n} = 7), chronic intestinal pseudo-obstruction (\textit{n} = 5), and gastroscisis (\textit{n} = 1). Patients currently on PN were younger, had

<table>
<thead>
<tr>
<th>Table 1: Patient characteristics.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All patients</strong></td>
</tr>
<tr>
<td>N</td>
</tr>
<tr>
<td>Boys</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
</tr>
<tr>
<td>Weight z-score</td>
</tr>
<tr>
<td>Height z-score</td>
</tr>
<tr>
<td>Duration of PN (mo)</td>
</tr>
<tr>
<td>Time after weaning off PN (y)</td>
</tr>
<tr>
<td>Weekly PN infusions</td>
</tr>
<tr>
<td>PN calories of total nutrition (%)</td>
</tr>
<tr>
<td>Time after last bowel resection (y)</td>
</tr>
<tr>
<td>SBS/dysmotility disorder (n)</td>
</tr>
</tbody>
</table>

**Remaining bowel**

|               |                 |                 |                 |     |
| Small bowel (cm)| 47 (25–101) | 30 (18–60) | 50 (31–108) | 0.031 |
| Small bowel (%)  | 26 (17–47)   | 23 (14–29)  | 32 (21–50) | 0.046 |
| Ileum (cm)       | 0 (0–5)      | 0 (0–4)     | 2 (0–18)   | 0.125 |
| Colon (%)        | 87 (57–100)  | 71 (22–100) | 95 (68–100)| 0.069 |
| ICV preserved (n) | 6             | 6            | 9           | 0.249 |
| Small intestinal endostomy (n)   | 4            | 3            | 1           | 0.083 |
| Serum Citrulline (umol/L)        | 22 (15–29)   | 13 (10–23)  | 24 (18–30) | 0.001 |
| Serum GLP-1 (ng/mL)              | 6.0 (4.0–16) | 4.1 (2.8–5.1)| 6.3 (5.1–21)| 0.005 |
| Serum GLP-2 (ng/mL)              | 20 (14–28)   | 19 (14–25)  | 20 (14–34) | 0.571 |

Data are median (IQR). GLP: glukagon-like-peptide, SBS: short bowel syndrome.
P-values refer to comparisons between patient groups using Fisher’s exact test or Mann Whitney U test. P-values <0.05 are marked bold.

\* \%: percentage of remaining age-adjusted small bowel or colon length.
shorter time since the latest bowel resection, and had shorter remaining absolute and age-adjusted small bowel length compared to patients, who had weaned off PN median 3.9 years before the study. Four patients had a small intestinal endostomy without colic continuity. Fourteen of the patients had undergone autologous intestinal reconstruction surgery, including serial transverse enteroplasty and tapering enteroplasty, median 3.1 (0.2–10) years before. Of them, six were currently on PN and eight had weaned off PN. Other baseline data, including BMI, weight and height z-scores were comparable between patients currently receiving PN and patients weaned off PN.

3.2. Serum GLP-1 and GLP-2 levels in relation to controls, PN-dependency and growth

Serum GLP-2 levels were similarly increased both in patients currently receiving PN [GLP-1 4.1 (2.8–5.1); GLP-2 19 (14–25)] and in patients who had weaned off PN [GLP-1 6.5 (5.1–21); GLP-2 20 (14–34)] when compared to controls [GLP-1 6.4 (3.9–10.7); GLP-2 11.6 (7.0–18.6)] (Fig. 1, Table 1). Serum GLP-1 levels were decreased in patients currently receiving PN, when compared to patients, who had weaned off PN and controls (Fig. 1).

Serum GLP-1 and GLP-2 levels associated with decreasing PN dependency as serum GLP-1 level correlated negatively with percentage of daily parenteral energy and serum GLP-2 with frequency of PN infusions (Fig. 2). During PN, serum GLP-1 levels correlated positively with age (r = 0.794, P < 0.001), time after the latest bowel resection (r = 0.794, P < 0.001), and duration of PN (r = 0.763, P = 0.002), whereas in controls both serum GLP-1 (r = −0.294, P = 0.045) and GLP-2 (r = −0.402, P = 0.007) correlated negatively with age.

In all patients, serum GLP-1 level correlated positively with weight z-score (r = 0.388, P = 0.005). After weaning off PN, weight z-score correlated positively with GLP-1 and GLP-2 (Fig. 3) and BMI with GLP-1 (r = 0.380, P = 0.032). Height z-score was not associated with serum GLP-1 or GLP-2 levels (P > 0.05 for both).

3.3. Serum GLP-1 and GLP-2 levels in relation to remaining intestine

As shown in Fig. 4, serum GLP-2 concentrations were higher in patients with small bowel-colic continuity [21.1 (15.0–30.7) ng/L] compared to patients who had weaned off PN and controls [9.4 (4.2–18.7) ng/L] (Fig. 4).
**Fig. 3.** After weaning off PN, weight z-score correlated with serum glukagon-like-peptide-1 (GLP-1) and -2 (GLP-2) levels. Spearman rank correlations.

**Fig. 4.** In patients on PN, serum GLP-2 levels were inversely associated with the remaining small bowel length. A Spearman rank correlation.

**Fig. 5.** Patients with small bowel-colic continuity had significantly higher serum glukagon-like-peptide-2 (GLP-2) levels compared to patients with a small intestinal endostomy or controls (A). Patients with ileum with and without ileum (B) and those with or without ileocecal valve, ICV, (C) had comparable levels of serum GLP-2. P-values for Mann Whitney U test between two groups are shown. The box plots display median, IQR, and range. Kruskall Wallis test $P < 0.001$ for all.
In adult short bowel patients with resected ileum, the percentage of daily PN calories and serum GLP-2 with frequency of GLP-1 and GLP-2 levels positively associated with decreasing PN requirements [8,13,14]. In this study, serum GLP-1 levels were decreased during PN, while serum GLP-2 levels were increased irrespective of whether or not patients were currently receiving PN. Whether the decreased serum GLP-1 levels during PN are related to limited food intake and nutrient induced secretion of GLP-1 remains unclear and require further studies. Serum GLP-2 levels were elevated not only during PN delivery but also after weaning off PN. This suggests that GLP-2 is not simply associated with the immediate adaptive response after resection, but is also important in the maintenance of the adaptive response [12]. Accordingly in the present study, serum GLP-2 levels were elevated not only during PN delivery and also after weaning off PN. Serum GLP-1 levels were decreased during PN, but elevated to the control level after weaning of PN. Both GLP-1 and GLP-2 serum levels correlated positively with weight z-score. These results suggest an ongoing contribution of GLP-1 and GLP-2 to intestinal adaption process in patients with pediatric onset IF.

This study had some limitations, including the cross-sectional study design, which provides association rather than prove of causality. In addition, the number of patients with an endostomy was limited and postprandial GLP levels were not measured. GLP-2 is secreted from ileal and colonic enteroendocrine L-cells in response to both proximal enteric neuronal signaling and the presence of luminal nutrients and bile acids. To better understand the connections between meal-stimulated GLP secretion and intestinal adaption, postprandial measurements of serum GLPs would be important by providing mechanistic information of the effects of enteral nutrition in weaned off patients compared to patients on PN. Despite these limitations, this study provides new clinical information on the GLP-1 and GLP-2 levels during intestinal adaptation in pediatric onset IF.

**Statement of authorship**

Study concept: MP; Study design: AM, MP; acquisition of data: AM; drafting of the manuscript: AM; critical revision of the manuscript for important intellectual content: MP; statistical analysis: AM; obtained funding: MP; study supervision: MP. AM and MP have approved the final article.

**Conflicts of interest**

The authors have no conflicts of interest.

**Financial support**

This study was supported by grants from the Finnish Pediatric Research Foundation, the Sigrid Juselius Foundation and the Helsinki University Central Hospital research funds.
References


